Cabaletta Bio Reports Third Quarter 2026 Financial Results
Cabaletta Bio announced its financial results for the third quarter ended September 30, 2026, and provided a business update regarding its clinical development programs.
Stocks · News reference
Wells Fargo Maintains Equal-Weight on Cabaletta Bio, Lowers Price Target to $3
Wells Fargo analyst Derek Archila maintains Cabaletta Bio (NASDAQ:CABA) with a Equal-Weight and lowers the price target from $4 to $3.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Cabaletta Bio Grants Inducement Equity Awards to New Employees
Cabaletta Bio announced the grant of inducement equity awards to four newly hired non-executive employees in accordance with Nasdaq Listing Rule 5635(c)(4).
8-K filing — Cabaletta Bio, Inc. (CABA)
Filed: 2026-11-05 AccNo: 0001759138-26-000046 Size: 336 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Cabaletta Bio Announces Participation in Upcoming Investor Conferences
Cabaletta Bio, Inc. announced it will participate in the Guggenheim 3rd Annual Healthcare Innovation Conference and the 2026 Jefferies Global Healthcare Conference in November 2026.
Lupus Nephritis Market on a Growth Trajectory at a CAGR of 7% During the Forecast Period (2026–2036), as Innovative Therapies Gain Momentum | DelveInsight
The lupus nephritis market is projected to grow at a 7% CAGR through 2036, driven by increasing disease awareness, improved diagnosis, and expanding adoption of targeted therapies. The market was valued at USD 2.1 billion in 2025 across seven major markets. Three therapies have received FDA approval (belimumab, voclosporin, and obinutuzumab), while a robust pipeline of innovative treatments including CAR-T therapies, complement inhibitors, and monoclonal antibodies is expected to transform disease management.
HC Wainwright & Co. Reiterates Buy on Cabaletta Bio, Maintains $16 Price Target